OKYO Pharma announced that CEO Robert J. Dempsey and CMO Flavio Mantelli will present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on July 22, 2026. The company also noted plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain (NCP). OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
